View Post

New Report Charts Dramatic Growth in the Global Clinical Trial Landscape for PD-1/L1 Immune Checkpoint Inhibitors

In Clinical Trials by Barbara Jacoby

From: cancerresearch.org 2,250 clinical trials are evaluating PD-1/L1 immune checkpoint inhibitors, an increase of 748 trials over the past year 1,716 trials are assessing regimens that combine PD-1/L1 immune checkpoints with other cancer therapies 240 drug targets are being evaluated in the current landscape, 75 more targets compared to a year ago Over 380,000 patient volunteers are required to fill …

View Post

New Clinical Research on Chimeric Antigen Receptor (CAR) T-Cell Therapy Presented at 60th American Society of Hematology Annual Meeting

In Clinical Trials by Barbara Jacoby

Source:    Yadira Galindo, Health Journalist The 60th American Society of Hematology (ASH) Annual Meeting, the largest international conference and exhibition in the field of hematology, is currently taking place at the San Diego Convention Center.  Dr. Peihua Lu, the Medical Executive President of the Hebei Yanda Lu Daopei Hospital, and Dr. Xian Zhang from the same institution were invited by …

View Post

QIAGEN and NeoGenomics collaborate to offer cancer patients Day-One access to innovative companion diagnostics for newly approved drugs

In Clinical Trials by Barbara Jacoby

Source: QIAGEN From: apnews.com Nov 30, 2018–QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and NeoGenomics, Inc. (NASDAQ: NEO) today announced a master service agreement to accelerate the availability of innovative companion diagnostics that enable precision medicine for cancer patients. The partnership between QIAGEN and NeoGenomics, a leading provider of cancer-focused genetic testing services, will ensure Day-One patient access to …

View Post

Proposed NRG-BN006 Phase 2/3 trial to begin enrollment in 2019

In Clinical Trials by Barbara Jacoby

Tocagen Inc. (TOCA), a late clinical-stage, cancer-selective gene therapy company and NRG Oncology, a member of the National Cancer Institute’s (NCI) National Clinical Trial Network (NCTN), today announced that the NCI Cancer Therapy and Evaluation Program (CTEP) Brain Malignancies Steering Committee has approved a concept to develop a clinical trial utilizing the investigational therapeutic regimen Toca 511 (vocimagene amiretrorepvec) & …

View Post

2 Trials, Now Enrolling, Aimed at Improving Breast Cancer Prevention, Diagnosis, and Treatment

In Clinical Trials by Barbara Jacoby

By: Patricia Inacio, PhD From: breastcancer-news.com The University of Hawaiʻi Cancer Center is enrolling participants in two clinical trials to test new ways of preventing and diagnosing breast cancer, as well as improving current treatments. “These trials are very important because breast cancer is a significant issue in Hawaiʻi,” Randall Holcombe, director of the UH Cancer Center said in a press release. “Racial and ethnic minority …

View Post

Aileron Enters Clinical Trial Collaboration With Pfizer To Evaluate ALRN-6924 In Combination With IBRANCE® (Palbociclib) In MDM2-Amplified Cancers

In Clinical Trials by Barbara Jacoby

Source: Aileron Therapeutics, Inc. From: clinicalleader.com Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer and other diseases, today announced that it has entered into a clinical trial collaboration with Pfizer to evaluate the combination of Aileron’s ALRN-6924 and Pfizer’s palbociclib, also known as IBRANCE®, in MDM2-amplified cancers. Overexpression of MDM2 in …

View Post

New dual-action cancer-killing virus

In Clinical Trials by Barbara Jacoby

From: eurekalert.org Scientists have equipped a virus that kills carcinoma cells with a protein so it can also target and kill adjacent cells that are tricked into shielding the cancer from the immune system. It is the first time that cancer-associated fibroblasts within solid tumours – healthy cells that are tricked into protecting the cancer from the immune system and …

View Post

Trials Answer Questions About Duration of Treatment in HER2+ Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Angelica Welch From: oncnursingnews.com The optimal duration of treatment for patients with HER2-positive breast cancer has been called into question by recent findings from the NSABP B-52, PERSEPHONE, and APT clinical trials. Priya Rastogi, MD, senior associate medical director, NSABP Medical Affairs, associate professor of Medicine, University of Pittsburgh, shed light on the subject during a presentation she gave …

View Post

Edge Therapeutics Enters into Merger Agreement with PDS Biotechnology to Form Clinical-Stage Cancer Immunotherapy Company

In Clinical Trials by Barbara Jacoby

-Merger would create publicly-traded immuno-oncology biotechnology company developing novel products for treating early- and late-stage cancer- -Growing product pipeline utilizing Versamune®, a novel, versatile, multi-functional platform- -Phase 1/2 clinical data on lead product candidate PDS0101 suggests immunotherapeutic anti-cancer activity and favorable safety profile in early stage cervical cancer- -Combined company plans to initiate multiple Phase 2b/3 clinical trials of PDS0101 …

View Post

Puma Biotechnology Presents Results of Patient Reported Outcomes in Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

In Clinical Trials by Barbara Jacoby

From: businesswire.com Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, is presenting updated results from a Phase II clinical trial of Puma’s drug neratinib at the 2018 San Antonio Breast Cancer Symposium (SABCS) that is currently taking place in San Antonio, Texas. The presentation entitled, “The impact of neratinib with or without anti-diarrheal prophylaxis on health-related quality of life in …